《新股消息》勛龍(01930.HK)下周一起招股入場費3,555.47元
中國定製模具開發商及主要供應商勛龍(01930.HK)將於下周一(17日)起至下周四(20日)招股,計劃發行1.65億股,其中10%為本港公開發售,90%作國際配售,每股招股價介乎0.8元至0.88元,按一手4,000股計,入場費3,555.47元。股份計劃6月28日於聯交所掛牌上市,獨家保薦人為博思融資。
按中間價每股0.84元計算,集資淨額約9,260萬元,當中76.3%將用於購買新生產設備;10%用於增補營運資金;6.5%用作購買軟件;4%用作新廠房租賃物業;3.2%用作廠房的一般設立成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.